LASSBio-881: an N-acylhydrazone transient receptor potential vanilloid subfamily type 1 antagonist orally effective against the hypernociception induced by capsaicin or partial sciatic ligation.
OBJECTIVE
Compound LASSBio-881 is an orally effective antinociceptive that binds to cannabinoid receptors and is active mainly on the neurogenic component of pain models. We investigated whether transient receptor potential vanilloid subfamily type 1 (TRPV1) channels are involved in the effects of LASSBio-881.


METHODS
Modulation of capsaicin (CAP)- and low pH-induced currents was evaluated in TRPV1-expressing Xenopus oocytes. In vivo effects were evaluated in CAP-induced acute and inflammatory changes in nociception, as well as in partial sciatic ligation-induced thermal hypernociception.


RESULTS
LASSBio-881 inhibited TRPV1 currents elicited by CAP with an IC(50) of 14 microM, and inhibited proton-gated currents by 70% at 20 microM. Functional interaction with CAP was surmountable. Locally applied LASSBio-881 decreased time spent in CAP-elicited nocifensive behaviour by 30%, and given orally it reduced measures of CAP- or carrageenan-evoked thermal hypernociception by 60 and 40% respectively. In addition, LASSBio-881 decreased the paw withdrawal responses to thermal stimuli of animals with sciatic neuropathy 7-11 days after nerve ligation, at a dose of 300 micromol*kg(-1)*day(-1) p.o. At this dose, hyperthermia was not observed within 4 h following oral administration.


CONCLUSIONS
LASSBio-881 is a TRPV1 antagonist that apparently competes with CAP. Accordingly, LASSBio- 881 inhibited nociception in models of acute, inflammatory and neuropathic pain presumed to involve TRPV1 signalling. These in vivo actions were not hindered by hyperthermia, a common side effect of other TRPV1 antagonists. We propose that the antinociceptive properties of LASSBio-881 are due to TRPV1 antagonism, although other molecular interactions may contribute to the effects of this multi-target drug candidate.
Tributino
J L M
JL
Universidade Federal do Rio de Janeiro, RJ, Brazil.
Santos
M L H
ML
Mesquita
C M
CM
Lima
C K F
CK
Silva
L L
LL
Maia
R C
RC
Duarte
C D
CD
Barreiro
E J
EJ
Fraga
C A M
CA
Castro
N G
NG
Miranda
A L P
AL
Guimaraes
M Z P
MZ
D000284:Administration, Oral; D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D002211:Capsaicin / Q000494:pharmacology*; D005260:Female; D006834:Hydrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D010146:Pain / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology; D051381:Rats; D017208:Rats, Wistar; D012584:Sciatic Nerve / Q000601:surgery*; D050916:TRPV Cation Channels / Q000037:antagonists & inhibitors*; D014982:Xenopus laevis
D000700:Analgesics; D006834:Hydrazines; C518927:LASSBio-881; D050916:TRPV Cation Channels; C494484:TRPV1 receptor; D002211:Capsaicin
J Pharmacol Exp Ther. 2005 Jul;314(1):410-21
15837818
J Pharmacol Exp Ther. 2003 Jan;304(1):56-62
12490575
Nature. 1997 Oct 23;389(6653):816-24
9349813
Br J Pharmacol. 2009 Nov;158 Suppl 1:S1-254
19883461
Nature. 2001 Jun 21;411(6840):957-62
11418861
Brain Res Rev. 2009 Apr;60(1):267-77
19150372
Science. 2000 Apr 14;288(5464):306-13
10764638
Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11165-9
15263079
Curr Med Chem. 2004 May;11(9):1147-62
15134512
Bioorg Med Chem. 2007 Mar 15;15(6):2421-33
17275312
Pain. 2005 Jan;113(1-2):51-60
15621364
Pharmacol Rev. 1999 Jun;51(2):159-212
10353985
Pain. 1990 Nov;43(2):205-218
1982347
J Neurosci. 2006 Sep 13;26(37):9385-93
16971522
Nature. 1999 Jul 29;400(6743):452-7
10440374
Chem Biol. 2007 Jul;14(7):741-56
17656311
Nat Rev Drug Discov. 2007 May;6(5):357-72
17464295
J Pharmacol Exp Ther. 2002 Jun;301(3):963-8
12023525
Eur J Neurosci. 2005 Jul;22(2):361-70
16045489
Braz J Med Biol Res. 2005 Mar;38(3):445-51
15761625
Neurosci Lett. 1997 Oct 10;235(1-2):73-6
9389599
Nature. 2000 May 11;405(6783):183-7
10821274
J Pharmacol Exp Ther. 2001 Nov;299(2):558-66
11602667
Br J Pharmacol. 2005 Mar;144(6):781-90
15685214
Science. 2003 May 23;300(5623):1284-8
12764195